Member Info for SYN00GOLD

Apart from the tone of the RNS being highly confident, re-EUA/commercialisation/FDA pathway etc etc my major take was that IF activ 2 p3 comes in next few days we are without doubt looking at SUBSTANTIAL rise from here. And these comments ignore THE most significant aspects IMO of the global P3 output being AMAZING and the big pharma in full snifter mode.

Luvvly jubbly :-)

Excellent RNS - No surprise that SP drops, just load up as best you can. I am seeing lots of green boxes for the 1st time in a long while !!!! Go figure. We have seen this all before. All get your rocket fuel before the pumps run dry :-)

As Ghia said earlier, and I could not say it any better...

'FDA EUA comment is the one I’ve been waiting for. They clearly think they’ve got the data, the manufacturing and the market to pull the trigger.'

The stars are aligning. Holllllllllllllllllllllllldddddddddddddddddddddddddddddddddd :-)

Thanks Titania - quite scary numbers. Lets hope RM can help alleviate the problem with a broad spectrum agnostic antiviral.

Hope you're keeping well Oak :-)

Earlier this year. Nice

Numis’s target price of 990p would give SNG a m.cap of over £1.5bn. While at first glance this may seem fairly lofty, it is hard to argue that SNG is due significant upside should its trial to be a success – a combination of successful trials, the inevitable confirmation of orders and a look into the future of the business should help it get near to this valuation. The big IF is around the trial, should this be a success, the rest will inevitably follow.
While news of vaccines and increased speed of roll-out is promising, the reality has since sunk in. Vaccines will take a great deal of time to be deployed and will not guarantee immunity for all, meanwhile COVID-19 is as dangerous and transmissible as ever.
Providing it is a success, SNG’s treatment will surely be at the top of the list for every hospital around the world, not only the NHS.
For investors willing to take a leap of faith, there does appear very significant reward on the table.

Mmmmmmmmwonder why the afternoon uplift :-)

From our very own Prof Wilk and Alistair Watson ONLY 6 months ago !!

Conclusion
COVID-19 has already caused >2.3?million deaths and has highlighted the impact and global burden of respiratory viral infections, particularly in the elderly. Although influenza is also a key respiratory pathogen, the importance of other respiratory viruses is starting to become apparent. Compared with young adults, respiratory viral infection in >65-year-olds is associated with increased morbidity and mortality. Elderly patients may present with severe lower respiratory tract infections, pneumonia or exacerbation of chronic multimorbidities. Further challenges are faced due to elderly patients often presenting without fever or respiratory symptoms but with atypical symptoms including weakness, confusion and falls. This leads to a failure in diagnosis, increased morbidity, prescription of additional medications and further nosocomial spread. It is now essential to introduce sensitive, rapid point-of-care diagnostics to identify all viruses and treat infected elderly patients. This will facilitate an understanding of the true burden of respiratory viruses. To protect the aging immune system, it is now key to couple this with the development of augmented vaccination strategies and novel anti-viral therapeutics.

SNG001 will be needed for many complications of respiratory diseases...….and still is a...……..

UK-based respiratory biotechnology company focused on drug discovery, development and commercialisation !!!

Thanks for the clarification Matml - I'm even more hopeful now :-)

UpdownWinlose - thanks

Very positive, we as a company are positioning extremely well. The future is rosy :-)

Looking forward to the output from Buzz et al in tomorrows analyst update. I'm certain commercialisation etc will be high on the agenda. I still believe the critical output is P3 globally. The Activ-2 for me is just some added gravy (if results show improvement in home environment). NUT biggie is Global P3

It's all very exciting and a great time to be a shareholder.

UpdownWinlose - thanks

Very positive, we as a company are positioning extremely well. The future is rosy :-)

Looking forward to the output from Buzz et al in tomorrows analyst update. I'm certain commercialisation etc will be high on the agenda. I still believe the critical output is P3 globally. The Activ-2 for me is just some added gravy (if results show improvement in home environment). NUT biggie is Global P3

It's all very exciting and a great time to be a shareholder.

Where it began, I can't begin to knowing
But then I know it's growing strong
Was in the spring
And spring became the summer
Who'd have believed SNG would come along
Lungs, touching airways
Reaching out, touching me, touching you
Sweet SNG 0 0 1
Good times never seemed so good
I've been inclined
To believe they never would
But now I
Look at the night and it don't seem so lonely
We filled it up with only shares
And when I hurt
Hurting runs off my shoulders
How can I hurt when holding you
One, touching one
Reaching out, touching me, touching you
Sweet SNG 0 0 1
Good times never seemed so good
I've been inclined
To believe they never would

Our time is coming Synners

Hoooooolllllllllllllllllllllllldddddddddddddddddddddddddd

Significant data is certainly incoming, as you suggest Q4, just about the when !

Great thing ongoing is the now drip feed of news on antiviral treatments becoming a flood. Only good news for us. Nice piece in Financial Times today with good quote from Buzz :-)

https://www.ft.com/content/48cf11f5-9588-4487-b262-f6f26e901ec2

Just wait till they catch up with MARA and RIOT :-)

Flying now !!! Hold tight

Still here :-)

Great work Oxford !!

The jigsaw is slowly starting to come together. We have all been here a long while. Think we can wait a bit longer for GOLD :-)

I view is that interest rates worldwide are fundamentally at rock bottom. 50K in premium bonds OR 50K in ARB, looking just 2 years from now >>>>>>>>

ARB will be minimum £5 plus. Easy LTH decision. Enjoy the day to day banter :-)

Should be a VERY interesting afternoon about 3.00pm.

Longer term is great investment.

poor grammar

'that' have etc

Great post TT.

I am of a similar view of the scenario you have expressed. If this was to discuss results of 'poor' outcomes etc, it would have to be announced to the market immediately via RNS. I believe that they will be discussing a 'potential' roadmap and maybe, highlighting discussions that are ongoing with 'other' relevant parties about moving forward and the opportunities what has been achieved in the past months.
Looking forward to the update on 30th Sept :-)

Great post TT.

I am of a similar view of the scenario you have expressed. If this was to discuss results of 'poor' outcomes etc, it would have to be announced to the market immediately via RNS. I believe that they will be discussing a 'potential' roadmap and maybe, highlighting discussions that are ongoing with 'other' relevant parties about moving forward and the opportunities what has been achieved in the past months.
Looking forward to the update on 30th Sept :-)